Tuberculosis, Multidrug-Resistant Clinical Trials

6 recruitingLast updated: May 21, 2026

There are 6 actively recruiting tuberculosis, multidrug-resistant clinical trials across 13 countries. Studies span Phase 2, Phase 3. Top locations include Dasmariñas, Philippines, Hanoi, Vietnam, Kampala, Uganda. Updated daily from ClinicalTrials.gov.


Tuberculosis, Multidrug-Resistant Trials at a Glance

6 actively recruiting trials for tuberculosis, multidrug-resistant are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Dasmariñas, Hanoi, and Kampala. Lead sponsors running tuberculosis, multidrug-resistant studies include Boston University, Janssen Research & Development, LLC, and National Institute of Allergy and Infectious Diseases (NIAID).

Browse tuberculosis, multidrug-resistant trials by phase

About Tuberculosis, Multidrug-Resistant Clinical Trials

Looking for clinical trials for Tuberculosis, Multidrug-Resistant? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Tuberculosis, Multidrug-Resistant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Tuberculosis, Multidrug-Resistant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB

Tuberculosis, Multidrug-Resistant
Janssen Research & Development, LLC60 enrolled11 locationsNCT02354014
Recruiting

Training Protocol on the Natural History of Tuberculosis

TuberculosisLatent TuberculosisMycobacterium Infections+2 more
National Institute of Allergy and Infectious Diseases (NIAID)150 enrolled1 locationNCT01212003
Recruiting
Phase 2Phase 3

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

Tuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosis, MDR
University of California, San Francisco400 enrolled6 locationsNCT06441006
Recruiting
Phase 3

A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients

Rifampin-Resistant Pulmonary TuberculosisTuberculosis, Multidrug-Resistant (MDR-TB)
Shanghai Jiatan Pharmatech Co., Ltd450 enrolled2 locationsNCT05824871
Recruiting
Phase 2

Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB

Tuberculosis, Multidrug-Resistant
Boston University220 enrolled2 locationsNCT03828201
Recruiting

Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia

Tuberculosis, Multidrug-Resistant
University of Namibia2,100 enrolled1 locationNCT05022238